• Schedule Your 340B Demos Now!

    The 2018 340B Coalition Summer Conference is just around the corner. July 9-11, we will be in Washington, D.C. as a Pinnacle Leader Sponsor for the conference, ready to connect with you and gain insight into the latest news and trends concerning the 340B Drug Discount Program. If you are attending, be sure to schedule… Read more »

  • Clinical Insights: June 13, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval FulphilaTM (pegfilgrastim-jmdb) – New Biosimilar Drug Approval – June 4, 2018 – The U.S. Food and Drug Administration approved FulphilaTM (pegfilgrastim-jmdb) as the first biosimilar to Neulasta®(pegfilgrastim) to… Read more »

  • Clinical Insights: May 1, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval JynarqueTM (tolvaptan) – April 24, 2018 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved JynarqueTM (tolvaptan) as… Read more »

  • Connect with Us at the CPS Annual Meeting & Vendor Expo

    May 2-4, Vice President – Implementations and Sales Support Ryen Brumbeloe and Sales Manager ­– Midwest Region Todd Hudnall will attend and exhibit at the Comprehensive Pharmacy Systems/Pharmacy Systems, Inc. (CPS) Annual Meeting & Vendor Expo in Indianapolis, IN. There, over 450 pharmacy decision makers will connect and gain insight into the latest industry news.… Read more »

  • Integrated Solutions to Maintain Program Compliance

    There are many challenges organizations face when maintaining a compliant 340B Drug Pricing Program. At RxStrategies, we specialize in delivering integrated solutions to assist implementation and compliance.   Split Billing Provides end-to-end 340B program management and addresses its complexity by reviewing all prescription activity to flag eligible 340B dispenses.   CompliancePlus Streamlines workflow, quickly indemnifies… Read more »

  • Clinical Insights: February 5, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval FirvanqTM (vancomycin hydrochloride) – January 29, 2018 – CutisPharma announced that the U.S. Food and Drug Administration (FDA) has approved Firvanq™ (vancomycin hydrochloride) for oral solution, for the… Read more »

  • Clinical Insights: January 15, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Formulation Approval No new updates.   New Indication Approval Lynparza® (olaparib) – January 12, 2018 – The Food and Drug Administration… Read more »

  • Join Us at the 340B Coalition Winter Conference!

    Join the RxStrategies team at the 340B Coalition Winter Conference in San Diego, California February 21-23. Here, your team can stay up to date on the latest news, trends and regulations in the 340B program to best maintain compliance. We look forward to connecting with industry leaders while gaining insight on 340B happenings and issues… Read more »

  • Clinical Insights: January 2, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lumify™ (brimonidine tartrate) – New OTC Drug Approval – December 22, 2017 – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary… Read more »